Search Results
You are looking at 1 - 2 of 2 items for
- Author: Albert Thiry x
- Refine by access: Content accessible to me x
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Department of Life Sciences, Centro de Investigação em Antropologia e Saúde, University of Coimbra, Coimbra, Portugal
Search for other papers by Daniel Fernandes in
Google Scholar
PubMed
Search for other papers by Frederic Fina in
Google Scholar
PubMed
Search for other papers by Mario Novak in
Google Scholar
PubMed
Search for other papers by Angelo Abati in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Albert Thiry in
Google Scholar
PubMed
Search for other papers by L’Housine Ouafik in
Google Scholar
PubMed
Search for other papers by Bertrand Pasture in
Google Scholar
PubMed
Search for other papers by Ron Pinhasi in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Vinciane Corman in
Google Scholar
PubMed
Search for other papers by Iulia Potorac in
Google Scholar
PubMed
Search for other papers by Florence Manto in
Google Scholar
PubMed
Search for other papers by Sarah Dassy in
Google Scholar
PubMed
Search for other papers by Karin Segers in
Google Scholar
PubMed
Search for other papers by Albert Thiry in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Breast cancer is rare in male patients. Certain predisposing factors, be they genetic (e.g., BRCA2 gene mutations) or hormonal (imbalance between estrogen and androgen levels), have been implicated in male breast cancer pathophysiology. Male-to-female (MtF) transsexualism is a condition that generally involves cross-sex hormone therapy. Anti-androgens and estrogens are used to mimic the female hormonal environment and induce the cross-sex secondary characteristics. In certain situations, the change in the hormonal milieu can be disadvantageous and favor the development of hormone-dependent pathologies, such as cancer. We report a case of a MtF transgender patient who developed breast cancer after 7 years of cross-sex hormonal therapy. The patient was found to be BRCA2 positive, and suffered recurrent disease. The patient was unaware of being a member of an established BRCA2 mutation-positive kindred. This represents the first case of a BRCA2 mutation predisposing to breast cancer in a MtF transgender patient.